The DNMT3A Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the DNMT3A gene has been disrupted to generate a loss-of-function model for de novo DNA methyltransferase activity. This product offers a heterogeneous pool of NCI-H1299 cells carrying diverse DNMT3A gene disruptions, providing a robust tool for studying CpG methylation and epigenetic gene silencing without the biases of clonal selection. The polyclonal format enables population-level analyses of DNA methylation dynamics and cellular phenotypes in a well-characterized lung adenocarcinoma background.
The host cell line, NCI-H1299, is a p53-deficient human non-small cell lung cancer (NSCLC) line derived from a lymph node metastasis of a lung adenocarcinoma. Its p53-null status eliminates a key transcriptional regulator of DNMT3A, making it an ideal context for dissecting p53-independent functions of DNMT3A. Widely employed as a metastatic lung adenocarcinoma model, NCI-H1299 cells are extensively used in cancer biology, drug response studies, and epigenetic research due to their reproducible growth characteristics and baseline methylation profile.
DNMT3A is a de novo DNA methyltransferase that methylates CpG dinucleotides, a critical step in epigenetic gene silencing during development and differentiation. It functions in complex with DNMT3L and cooperates with DNMT1, UHRF1, HDAC1, and EZH2 to couple DNA methylation and histone modifications. Transcriptional regulation involves SP1, MYC, and PI3K/AKT signaling; in NCI-H1299 cells, the absence of p53 further deregulates this control. Downstream targets include tumor suppressor genes CDKN2A (p16), CDH1 (E-cadherin), RASSF1A, and MGMT, whose silencing by DNMT3A-mediated methylation promotes a repressive chromatin state. Thus, DNMT3A disruption may reactivate these targets and alleviate epigenetic repression.
In the p53-null NCI-H1299 lung adenocarcinoma background, DNMT3A knockout disrupts de novo methylation machinery, potentially reactivating silenced tumor suppressors such as CDKN2A and CDH1, and altering cellular phenotypes including proliferation, migration, and drug sensitivity. This model isolates p53-independent functions of DNMT3A, offering a platform to dissect epigenetic contributions to metastatic behavior. The polyclonal nature captures a spectrum of knockout alleles, mirroring intratumoral heterogeneity and enabling robust analysis of methylation-dependent phenotypic variation.
This knockout cell model is well-suited for DNA methylation analysis via bisulfite sequencing, gene expression profiling by RT-qPCR, and protein detection through western blot. Functional assays such as colony formation, migration, and invasion can delineate the impact of DNMT3A loss on tumorigenic properties. It also serves as a tool for drug sensitivity testing with hypomethylating agents and investigating epigenetic therapy resistance. Applications include tumor suppressor reactivation studies and DNA methylation biomarker discovery in lung cancer. For further details, please contact Ascent Research.
